Alternative access in high-risk patients in the era of transfemoral aortic valve replacement. Issue 6 (1st August 2022)
- Record Type:
- Journal Article
- Title:
- Alternative access in high-risk patients in the era of transfemoral aortic valve replacement. Issue 6 (1st August 2022)
- Main Title:
- Alternative access in high-risk patients in the era of transfemoral aortic valve replacement
- Authors:
- Zubarevich, Alina
Szczechowicz, Marcin
Jánosi, Rolf-Alexander
Lind, Alexander
Rassaf, Tienush
Malik, Rizwan
Thielmann, Matthias
Schmack, Bastian
Kamler, Markus
Ruhparwar, Arjang
Weymann, Alexander
Wendt, Daniel - Abstract:
- Abstract: Background: We aimed to evaluate the outcomes of transapical and transaortic transcatheter aortic valve replacement (TAVR) in high-risk patients who were not suitable for transfemoral access and had a logistic EuroSCORE- I ≥ 25% and Society of Thoracic Surgeons (STS) score >6%. 'STS/ACC TAVR In-Hospital Mortality Risk App' was evaluated. Material and methods: Between January 2016 and May 2020, 126 patients at very high risk for aortic valve replacement underwent transapical ( n = 121) or transaortic ( n = 5) transcatheter aortic valve replacement. TAVR was performed using SAPIEN 3™ or ACURATE TA™ prosthesis. Results: The logistic EuroSCORE-I was 40.6 ± 14.0%, the STS-score 7.9 ± 4.6%, and STS/ACC-score 8.4 ± 3.4%. Valve implantation was successful in all patients. Operative, in-hospital and 30-days mortality, were 0, 7.9, and 13.5%, respectively. Survival was 72% at one year and 48% at four years. Expected/observed in-hospital mortality was 1.0 for the STS-score and 1.06 for the STS/ACC-score. Renal failure, low ejection fraction, and postoperative acute kidney injury, hemorrhage, and vascular complications were identified as independent predictors for 30-day mortality. Conclusions: Transapical and transaortic TAVR in high-risk patients unsuitable for transfemoral access is still a reasonable alternative in these patients. STS and STS/ACC-score appear to be highly accurate in predicting in-hospital mortality in high-risk patients undergoing TAVR.
- Is Part Of:
- Minimally invasive therapy & allied technologies. Volume 31:Issue 6(2022)
- Journal:
- Minimally invasive therapy & allied technologies
- Issue:
- Volume 31:Issue 6(2022)
- Issue Display:
- Volume 31, Issue 6 (2022)
- Year:
- 2022
- Volume:
- 31
- Issue:
- 6
- Issue Sort Value:
- 2022-0031-0006-0000
- Page Start:
- 909
- Page End:
- 916
- Publication Date:
- 2022-08-01
- Subjects:
- Aortic valve disease -- transcatheter valve implantation -- risk stratification
Endoscopy -- Periodicals
Interventional radiology -- Periodicals
Endoscopic surgery -- Periodicals
617.05 - Journal URLs:
- http://informahealthcare.com/loi/mit ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/13645706.2021.2015392 ↗
- Languages:
- English
- ISSNs:
- 1364-5706
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5797.714000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 22967.xml